Patients with metastatic melanoma who are overweight or obese have improved outcomes when treated with immunotherapies or targeted therapies. A recent study provides the first evidence that the host metabolic state influences the tumor metabolic phenotype, with implications for tumor progression and therapeutic response. See related article by Hahn et al., p. 154.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1158/1078-0432.CCR-22-3028 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!